⌕
Travere Therapeutics · TVTX · Nasdaq
Tenet 43 · Weak
Compare
$51.10+2.82%At closeTenet 43 · Weak
$51.10+1.40 (+2.82%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Travere Therapeutics (TVTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~38.9%/yr (FY21→FY25), net margin −5.2%. Worth your attention in FY25: Share count (+49.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲110.5%
490.7
FY21→FY25CAGR +38.9%/yr
Net income ($M)▲92.1%
−25.5
FY21→FY25CAGR —
Free cash flow ($M)—
—
no FY25 valueCAGR —
Diluted EPS▲92.9%
−0.29
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+49.1%

59.8mn → 89.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)490.7Revenue−10.3COGS480.4Gross profit−206.0R&D−337.2SG&A−62.8Op income37.3Tax & other−25.5Net income

-5¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 97.1% → 97.9%. Net margin -5.2% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
651,034.0490,728.0233,175.0145,238.0109,460.0131,836.0▲110.5%+38.9%
Cost of revenue
9,545.010,339.07,744.011,450.04,420.03,818.0▲33.5%+28.3%
Gross profit
641,489.0480,389.0225,431.0133,788.0105,040.0128,018.0▲113.1%+39.2%
Research & development
358,666.0206,011.0282,701.0244,990.0227,333.0201,159.0▼27.1%+0.6%
Selling, general & admin
417,942.0337,202.0264,119.0265,542.0197,520.0126,284.0▲27.7%+27.8%
Total operating expenses
774,986.0543,213.0549,258.0521,926.0424,853.0327,443.0▼1.1%+13.5%
Operating incomefeeds ROC rank
−133,497.0−62,824.0−323,827.0−388,138.0−319,813.0−199,425.0▲80.6%—
Other income, net
−26,223.013,551.03,317.012,028.0−11,342.0−17,458.0——
Pretax income
−159,720.0−49,273.0−320,510.0−376,110.0−331,155.0−216,883.0▲84.6%—
Income tax
−5,298.0988.0120.0223.0313.0409.0▲723.3%+24.7%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−121,507.0−25,546.0−321,545.0−111,399.0−278,482.0−180,091.0▲92.1%—
Per share
Diluted EPSbuyback-sensitive
−1.28−0.29−4.08−1.50−4.37−3.01▲92.9%—
Diluted shares (mn)
94.6389.2178.8974.2763.7659.83▲13.1%+10.5%
Margins
Gross margin96th pct in Healthcare
98.5%97.9%96.7%92.1%96.0%97.1%▲1.2pp+0.8pp
Operating margin
−20.5%−12.8%−138.9%−267.2%−292.2%−151.3%▲126.1pp+138.5pp
Net margin22nd pct in Healthcare
−18.7%−5.2%−137.9%−76.7%−254.4%−136.6%▲132.7pp+131.4pp
† TTM = trailing four quarters through 2026-09-30.
FY11 – FY20 · 10 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Travere Therapeutics' revenue last fiscal year?

Travere Therapeutics reported revenue of $490.7M in fiscal 2025, up 110.5% from fiscal 2024.

What was Travere Therapeutics' net income?

Travere Therapeutics reported net income of −$25.5M in fiscal 2025, a net margin of −5.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.